11 Result(s)

Article

An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression

Natural killer (NK) cells are innate cytotoxic lymphocytes that play a fundamental role in the immunosurveillance of cancers. NK cells of cancer patients exhibit impaired function mediated by immunosuppressive...

Rika Fujii, Caroline Jochems, Sarah R. Tritsch… in Cancer Immunology, Immunotherapy (2018)

Reference Work Entry In depth

B7.1

Compared to oncogenes and tumor-associated antigens (TAAs), B7-1 is not a traditional cancer target as it is not expressed on the vast majority of solid tumors (Lenschow et al., Annu Rev Immunol 14:233–258, 19...

James W. Hodge, Amanda L. Boehm, Renee N. Donahue in Cancer Therapeutic Targets (2017)

Living Reference Work Entry In depth

B7.1

Compared to oncogenes and tumor-associated antigens (TAAs), B7-1 is not a traditional cancer target as it is not expressed on the vast majority of solid tumors (Lenschow et al. 1996). Nevertheless, B7-1 has be...

James W. Hodge, Amanda L. Boehm, Renee N. Donahue in Cancer Therapeutic Targets

Article

Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses

The 5-year survival rate for stage IB-III non-small-cell lung cancer (NSCLC) remains 15%. Surgical resection followed by adjuvant chemotherapy with cisplatin and vinorelbine is one standard-of-care. We sought ...

Sofia R. Gameiro, Jorge A. Caballero, Jack P. Higgins… in Cancer Immunology, Immunotherapy (2011)

Article

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

A concurrent multicenter, randomized Phase II trial employing a recombinant poxviral vaccine provided evidence of enhanced median overall survival (OS) (p = 0.0061) in patients with metastatic castrate-resistant ...

James L. Gulley, Philip M. Arlen, Ravi A. Madan… in Cancer Immunology, Immunotherapy (2010)

Article

Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations

Studies comparing two or more vaccine platforms have historically evaluated each platform based on its ability to induce an immune response and may conclude that one vaccine is more efficacious than the other(...

Amanda L. Boehm, Jack Higgins, Alex Franzusoff… in Cancer Immunology, Immunotherapy (2010)

Article

Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects

Radiolabeled monoclonal antibodies (mAb) have demonstrated measurable antitumor effects in hematologic malignancies. This outcome has been more difficult to achieve for solid tumors due, for the most part, to ...

Mala Chakraborty, Alexander Gelbard… in Cancer Immunology, Immunotherapy (2008)

Article

Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity

Systemic IL-2 is currently employed in the therapy of several tumor types, but at the price of often severe toxicities. Local vector mediated delivery of IL-2 at the tumor site may enhance local effector cell ...

Chie Kudo-Saito, Charlie T. Garnett… in Cancer Immunology, Immunotherapy (2007)

Article

The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses

Blockade of CTLA-4 by monoclonal antibodies (mAb) can mediate regression of tumors and increase the efficacy of tumor antigen specific vaccines. Blockade of CTLA-4 has also been shown to significantly increase...

Mala Chakraborty, Jeffrey Schlom, James W. Hodge in Cancer Immunology, Immunotherapy (2007)

Article

Carcinoembryonic antigen as a target for cancer vaccines

James W. Hodge, J. Schlom in Cancer Immunology, Immunotherapy (1996)